XOMA Corporation to Post Q3 2017 Earnings of ($0.80) Per Share, Wedbush Forecasts (XOMA)
XOMA Corporation (NASDAQ:XOMA) – Wedbush cut their Q3 2017 earnings estimates for shares of XOMA Corporation in a research note issued on Monday. Wedbush analyst L. Moussatos now expects that the biotechnology company will post earnings of ($0.80) per share for the quarter, down from their previous forecast of ($0.65). Wedbush currently has a “Hold” rating on the stock. Wedbush also issued estimates for XOMA Corporation’s Q4 2017 earnings at ($0.51) EPS, FY2017 earnings at ($2.75) EPS, Q1 2018 earnings at ($0.52) EPS, Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.51) EPS, Q4 2018 earnings at ($0.38) EPS, FY2018 earnings at ($1.95) EPS, FY2019 earnings at ($1.16) EPS, FY2020 earnings at ($1.80) EPS and FY2021 earnings at ($1.66) EPS.
A number of other research firms also recently weighed in on XOMA. Zacks Investment Research upgraded XOMA Corporation from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Friday, July 14th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of XOMA Corporation in a report on Thursday, August 10th. Finally, ValuEngine upgraded XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.67.
Shares of XOMA Corporation (NASDAQ XOMA) opened at 7.35 on Wednesday. The company’s 50 day moving average price is $7.21 and its 200-day moving average price is $6.35. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $13.98. The firm’s market capitalization is $55.75 million.
A hedge fund recently bought a new stake in XOMA Corporation stock. Stonepine Capital Management LLC acquired a new position in XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation comprises about 0.4% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Stonepine Capital Management LLC owned about 1.17% of XOMA Corporation as of its most recent SEC filing. 31.30% of the stock is owned by institutional investors and hedge funds.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.